Literature DB >> 33786233

A Rare Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation Associated With Typical Cystic Fibrosis in an Arab Child.

Aji Mathew1, Mohammed Dirawi2, Ahmad Abou Tayoun3, Rizwana Popatia4.   

Abstract

Cystic fibrosis (CF) is a progressive genetic disorder, inherited by the autosomal recessive mode of inheritance and more frequently seen in the Caucasian population with a carrier rate of 1:29 in Caucasian-Americans. Over 1800 cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations have been identified so far and the delta F 508 del mutation is the most common mutation. Gene sequencing and deletion/duplication analysis can detect mutations in 99% of people with a clinical diagnosis of CF. However, diagnostic testing can be challenging, as screening tests may be inconclusive and the routine gene mutation panel analysis may be negative due to some rare or undocumented mutations. We report a case of a two-year-old boy of Palestinian-Lebanese descent, with a history of raised immunoreactive trypsin test (IRT), positive sweat test, and phenotypical CF manifestations, found to have rare CF apparent homozygous CFTR (NM_000492.3) variant, c.3623del (p.Gly1208AlafsX3). In our case, genetic testing for 139 mutations done in Germany could not identify any defect. Only CFTR gene sequencing identified the above pathogenic variant. This reinforces the practice for a broad range of CFTR mutation analyses to detect ethnic-specific rare variants. This is the second case of this particular genetic mutation identified and the first to be reported in detail.
Copyright © 2021, Mathew et al.

Entities:  

Keywords:  cftr gene; pancreatic insufficiency

Year:  2021        PMID: 33786233      PMCID: PMC7994952          DOI: 10.7759/cureus.13526

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  13 in total

1.  UMD-CFTR: a database dedicated to CF and CFTR-related disorders.

Authors:  Corinne Bareil; Corinne Thèze; Christophe Béroud; Dalil Hamroun; Caroline Guittard; Céline René; Damien Paulet; Marie des Georges; Mireille Claustres
Journal:  Hum Mutat       Date:  2010-09       Impact factor: 4.878

2.  Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy.

Authors:  Erika J Sims; Allan Clark; Jonathan McCormick; Gita Mehta; Gary Connett; Anil Mehta
Journal:  Pediatrics       Date:  2007-01       Impact factor: 7.124

Review 3.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.

Authors:  M J Welsh; A E Smith
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

4.  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion.

Authors:  Ahmad N Abou Tayoun; Tina Pesaran; Marina T DiStefano; Andrea Oza; Heidi L Rehm; Leslie G Biesecker; Steven M Harrison
Journal:  Hum Mutat       Date:  2018-09-07       Impact factor: 4.878

Review 5.  Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review.

Authors:  Duaa Al-Sadeq; Taghreed Abunada; Rajaa Dalloul; Sara Fahad; Sara Taleb; Kholoud Aljassim; Fatima Alzahra Al Hamed; Hatem Zayed
Journal:  Respirology       Date:  2018-11-12       Impact factor: 6.424

6.  Comparison of the clinical manifestations of cystic fibrosis in black and white patients.

Authors:  A Hamosh; S C FitzSimmons; M Macek; M R Knowles; B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-02       Impact factor: 4.406

7.  A comprehensive assay for CFTR mutational analysis using next-generation sequencing.

Authors:  Ahmad N Abou Tayoun; Christopher D Tunkey; Trevor J Pugh; Tristen Ross; Minita Shah; Clarence C Lee; Timothy T Harkins; Wendy A Wells; Laura J Tafe; Christopher I Amos; Gregory J Tsongalis
Journal:  Clin Chem       Date:  2013-06-17       Impact factor: 8.327

8.  Analysis of four diverse population groups indicates that a subset of cystic fibrosis mutations occur in common among Caucasians.

Authors:  G R Cutting; S M Curristin; E Nash; B J Rosenstein; I Lerer; D Abeliovich; A Hill; C Graham
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

9.  Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients.

Authors:  Ozgül M Alper; Lee-Jun C Wong; Suzanne Young; Michelle Pearl; Steve Graham; John Sherwin; Eliezer Nussbaum; Dennis Nielson; Arnold Platzker; Zoe Davies; Allan Lieberthal; Terry Chin; Greg Shay; Karen Hardy; Martin Kharrazi
Journal:  Hum Mutat       Date:  2004-10       Impact factor: 4.878

10.  The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing.

Authors:  Iris Schrijver; Lynn Pique; Steve Graham; Michelle Pearl; Athena Cherry; Martin Kharrazi
Journal:  J Mol Diagn       Date:  2016-01       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.